Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN28SH
|
|||
| Drug Name |
Descartes-11
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 2 | [1] | |
| Company |
Cartesian Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell maturation protein (TNFRSF17) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04436029) Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Cartesian Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.